Free Trial
NASDAQ:IMNN

Imunon (IMNN) Stock Price, News & Analysis

Imunon logo
$0.78 -0.05 (-6.06%)
(As of 11/12/2024 ET)

About Imunon Stock (NASDAQ:IMNN)

Key Stats

Today's Range
$0.76
$0.84
50-Day Range
$0.80
$1.14
52-Week Range
$0.48
$3.65
Volume
440,248 shs
Average Volume
980,037 shs
Market Capitalization
$46.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Strong Buy

Company Overview

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

IMNN MarketRank™: 

Imunon scored higher than 68% of companies evaluated by MarketBeat, and ranked 224th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Imunon has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Imunon has only been the subject of 2 research reports in the past 90 days.

  • Read more about Imunon's stock forecast and price target.
  • Earnings Growth

    Earnings for Imunon are expected to grow in the coming year, from ($1.71) to ($0.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Imunon has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Imunon's valuation and earnings.
  • Percentage of Shares Shorted

    3.52% of the float of Imunon has been sold short.
  • Short Interest Ratio / Days to Cover

    Imunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Imunon does not currently pay a dividend.

  • Dividend Growth

    Imunon does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.52% of the float of Imunon has been sold short.
  • Short Interest Ratio / Days to Cover

    Imunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Imunon has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Imunon this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Imunon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Imunon is held by insiders.

  • Percentage Held by Institutions

    Only 4.47% of the stock of Imunon is held by institutions.

  • Read more about Imunon's insider trading history.
Receive IMNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

IMNN Stock News Headlines

Analysts Set Expectations for Imunon Q1 Earnings
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Imunon presents data from Phase 2 OVATION 2 clinical trial
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
See More Headlines

IMNN Stock Analysis - Frequently Asked Questions

Imunon's stock was trading at $0.68 at the beginning of 2024. Since then, IMNN shares have increased by 12.6% and is now trading at $0.7660.
View the best growth stocks for 2024 here
.

Imunon, Inc. (NASDAQ:IMNN) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.04.

Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO).

Company Calendar

Last Earnings
8/14/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNN
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+1,363.4%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-19,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$1.42 per share

Miscellaneous

Free Float
57,051,000
Market Cap
$49.24 million
Optionable
Not Optionable
Beta
2.14
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:IMNN) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners